Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia

Stroke. 2010 May;41(5):1001-7. doi: 10.1161/STROKEAHA.109.577288. Epub 2010 Mar 4.

Abstract

Background and purpose: Treatment with a selective proteasome inhibitor, VELCADE, in combination with tissue plasminogen activator (tPA) extended the therapeutic window to 6 hours in young rats after stroke. However, stroke is a major cause of death and disability in the elderly. The present study investigated the effect of VELCADE in combination with a low-dose tPA on aged rats after embolic stroke.

Methods: Male Wistar rats at the age of 18 to 20 months were treated with VELCADE (0.2 mg/kg) alone, a low-dose tPA (5 mg/kg) alone, combination of VELCADE and tPA, or saline 2 hours after embolic middle cerebral artery occlusion. To test the contribution of endothelial nitric oxide synthase to VELCADE-mediated neuroprotection, endothelial nitric oxide synthase knockout and wild-type mice were treated with VELCADE (0.5 mg/kg) 2 hours after embolic stroke.

Results: Treatment with VELCADE significantly reduced infarct volume, whereas tPA alone did not reduce infarct volume and aggravated blood-brain barrier disruption in aged rats compared with saline-treated rats. However, the combination treatment significantly enhanced the reduction of infarct volume, which was associated with an increase in endothelial nitric oxide synthase activity compared with saline-treated rats. Additionally, the combination treatment promoted thrombolysis and did not increase the incidence of hemorrhage transformation. VELCADE significantly reduced lesion volume in wild-type mice but failed to significantly reduce lesion volume in endothelial nitric oxide synthase knockout mice.

Conclusions: Treatment with VELCADE exerts a neuroprotective effect in aged rats after stroke. The combination of VELCADE with the low-dose tPA further amplifies the neuroprotective effect. Endothelial nitric oxide synthase at least partly contributes to VELCADE-mediated neuroprotection after stroke.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aging / drug effects*
  • Aging / pathology
  • Animals
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Brain Ischemia / enzymology
  • Brain Ischemia / pathology
  • Brain Ischemia / prevention & control*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Intracranial Embolism / enzymology
  • Intracranial Embolism / pathology
  • Intracranial Embolism / prevention & control*
  • Male
  • Neuroprotective Agents / administration & dosage*
  • Protease Inhibitors / administration & dosage
  • Pyrazines / administration & dosage*
  • Rats
  • Rats, Wistar
  • Tissue Plasminogen Activator / administration & dosage*

Substances

  • Boronic Acids
  • Neuroprotective Agents
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib
  • Tissue Plasminogen Activator